Liver X Receptor Agonism Sensitizes a Subset of Hepatocellular Carcinoma to Sorafenib by Dual-Inhibiting MET and EGFR

Sorafenib is the first approved systemic therapy for advanced hepatocellular carcinoma (HCC) and is the first-line choice in clinic. Sustained activation of receptor tyrosine kinases (RTKs) is associated with low efficacy of sorafenib in HCC. Activation of liver X receptor (LXR) has been reported to...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Weiqing, Zhu, Wenwei, Lin, Jing, Luo, Mengjun, Lin, Zhifei, Lu, Lu, Jia, Huliang, Qin, Lunxiu, Lu, Ming, Chen, Jinhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2019
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6911865/
https://www.ncbi.nlm.nih.gov/pubmed/31751859
http://dx.doi.org/10.1016/j.neo.2019.08.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6911865/
https://www.ncbi.nlm.nih.gov/pubmed/31751859
http://dx.doi.org/10.1016/j.neo.2019.08.002

Ejemplares similares